2025-521565-27-00撤回3 期
A randomized, multicenter, multiple-dose, double-blind, placebo-controlled, parallel-group design, clinical endpoint bioequivalence study to evaluate the therapeutic equivalence and safety of fluticasone furoate and vilanterol inhalation powder 100 mcg/25 mcg (Sandoz) and BREO® ELLIPTA® (fluticasone furoate and vilanterol inhalation powder) 100 mcg/25 mcg (GlaxoSmithKline) in adult participants with asthma
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 120
- 试验地点
- 8
- 主要终点
- FEV1 AUC0-24h on the first day of the treatment
研究概览
简要总结
To demonstrate the therapeutic equivalence of a generic fluticasone furoate and vilanterol inhalation powder 100 mcg/25 mcg (Sandoz) and BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder) 100 mcg/25 (GlaxoSmithKline) mcg in adult participants with asthma
To demonstrate the superiority of fluticasone furoate and vilanterol inhalation powder 100 mcg/25 mcg (Sandoz) and BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder) 100 mcg/25 (GlaxoSmithKline) over placebo in adult participants with asthma.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Capable of giving signed informed consent (as described in the protocol), which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol.
- •Participants who are currently non-smoking and have not used tobacco products (ie, cigarettes, cigars, vaping products, or pipe tobacco) or smoked marijuana products, within the past year. Note: Ex-smokers with ≤10 pack-years (i.e, one pack per day for 10 years) of historical use are allowed.
- •Participants who are able to replace their current regularly scheduled short acting β2‑agonists (SABAs) with a salbutamol/albuterol inhaler for use only on an ‘as-needed’ basis for the duration of the study. Note: Participants must also be able to withhold all inhaled SABA (rescue medication) for at least 6 hours prior to spirometry assessments on study visits.
- •Participants must be able to discontinue their asthma medications during the Run-in period, and for the remainder of the study.
- •Participants who can demonstrate the correct use of inhaler device (during the Run-in period and at Randomization visit).
- •Participants are eligible to participate in this study if they are: a) Of nonchildbearing potential. b) Of childbearing potential, and if they agree to use a highly effective form of contraception as per the contraceptive guidance consistently during the study, starting at Screening and until the EOS. These participants must have a negative pregnancy test at Screening and Randomization visit. c) Participants who produce viable sperm and have a partner of childbearing potential, and if they agree to use an adequate method of contraception as per the contraceptive guidance consistently during the study, starting at Screening and until the EOS and also refrain from donating sperm during this period. Participants with a partner or partners who is (are) not of childbearing potential are exempt from these requirements.
- •Participants should not receive treatment for their asthma exacerbation with any prohibited medications.
- •Participants must be 18 to 75 years old (inclusive) at Screening (signing the ICF).
- •Diagnosis of asthma, as defined by the National Asthma Education and Prevention Program, at least 12 weeks prior to Screening.
- •Participants who are stable on their chronic asthma treatment regimen for at least 4 weeks prior to Screening.
- •Pre-bronchodilator FEV1 of >40% and <85% of predicted value, at screening. Note: This test may be repeated once on a different day, within one week of the Screening Visit, due to inadequate treatment withholding, suboptimal technique, or technical failure.
- •Participants with FEV1 reversibility of ≥12% and ≥200 mL within 30 minutes following 360 mcg of albuterol inhalation (via pressurized metered dose inhaler [pMDI]) or equivalent at Screening
排除标准
- •Participants who have life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma-related syncopal episodes(s), or hospitalizations within one year prior to Screening or during the Run-in period.
- •Participants receiving systemic, oral, parental or depot corticosteroids or anti-IgE therapy withing 12 weeks prior to Screening spirometry or unable to stop receiving these medications during the study.
- •Participants receiving B2-blockers, anti-arrhythmics, anti-depressants, monoamine oxidase inhibitors, cytochrome P450 3A4 inhibitors, or diuretics within 4 weeks prior to the Screening spirometry or unable to stop receiving these medications during the study.
- •Participants receiving monoclonal antibodies that may affect the course of asthma withing 180 days prior to the Screening spirometry or unable to stop receiving these medications during the study.
- •Participants receiving live attenuated vaccines withing two days prior to Screening.
- •Participants who received an investigational drug within 28 days or 5 half-lives (whichever is longer) prior to Screening.
- •Hypersensitivity to any sympathomimetic drug (e.g., albuterol, vilanterol) or to any inhaled, intranasal, or systemic corticosteroid therapy, or to milk proteins, or to excipients in the dry powder inhaler.
- •Participants with significant alcohol or controlled substance abuse in the past 6 months, per the judgement of the Investigator.
- •Participants with any factors (e.g., infirmity, disability, or geographic location) that the Investigators feel would likely limit the participant’s compliance with the study protocol or scheduled clinic visits.
- •Participants who cannot communicate reliably or who are unlikely to co-operate with the requirements of the study, in the opinion of the Investigator.
- •Participants who are pregnant, breastfeeding, or planning to become pregnant during the study.
- •Participants with significant chronic respiratory disease (COPD, interstitial lung disease, etc) other than asthma which in the opinion of the investigator may interfere with the study evaluation or optimal participation in the study.
- •Participants with evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, cardiac dysrhythmia, significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that in the opinion of the Investigator, would put them at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
- •Participants with asthma exacerbations (i.e, acute or sub-acute worsening in symptoms and lung function from the participant’s usual status) within 6 weeks prior to Screening or during the Run-in period.
- •Participants with evidence or history of tuberculosis (additionally confirmed with a chest X-ray done within 6 months prior to Screening for countries with high tuberculosis risk).
- •Participants with uncontrolled allergic rhinitis within 15 days prior to screening.
- •Viral, bacterial, fungal, or parasitic, acute upper or lower respiratory tract infection (including COVDI-19), or sinus, or middle ear infection within 4 weeks prior to Screening, during the Run-in period, or at the Randomization visit. Note: Rescreening of participants with acute respiratory conditions during the Screening and Run-in period may be allowed in consultation with Medical Monitor.
- •Participants with a history of hepatitis B, hepatitis C, or human immunodeficiency virus 1 and
- •Participants with clinically significant screening laboratory and electrocardiogram (ECG) parameters as per the Investigator’s assessment.
结局指标
主要结局
FEV1 AUC0-24h on the first day of the treatment
FEV1 AUC0-24h on the first day of the treatment
FEV1 measured in the morning prior to the dosing of inhaled medications on the last day of the 4-week treatment period. Note: The primary endpoints will be baseline-adjusted (change from baseline).
FEV1 measured in the morning prior to the dosing of inhaled medications on the last day of the 4-week treatment period. Note: The primary endpoints will be baseline-adjusted (change from baseline).
次要结局
- Adverse events (including TEAEs, SAEs, and/or AEs leading to study medication/study discontinuation), vital signs, and physical examination findings.
研究者
Bill Brashier
Scientific
Sandoz Private Limited
研究点 (8)
Loading locations...
相似试验
进行中（未招募）
Unknown
To know whether the newer drug combination i.e. Vilanterol-Fluticasone is better than the conventionally use combination Formoterol-Budesonide in terms of effectiveness in controlling asthma symptoms and improving lung function in stable asthma patients or not.CTRI/2023/05/052174Department of Pulmonary, Critical Care and sleep Medicine
已完成
1 期
Relovair PD PK in Chinese Healthy SubjectsAsthmaNCT01711463GlaxoSmithKline16
已完成
3 期
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent AsthmaticsAsthmaNCT01134042GlaxoSmithKline587
已完成
1 期
A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy VolunteersBioequivalenceNCT04546256Respirent Pharmaceuticals Co Ltd.14
尚未招募
3 期
A comparison of vilanterol/Fluticasone furoate with Formoterol/Budesonide in the management of bronchial asthmaCTRI/2024/03/064848SRM College of Pharmacy